News ArticleNirma Limited Sells 36.8 lakh Shares, Cuts Stake in Alivus Life Sciences to 71.74%
Open market sale on 6th November 2026 reduces promoter shareholding by 2.99%, disclosed under SEBI takeover regulations
Nirma Limited, the promoter of Alivus Life Sciences Limited, has sold 36,80,000 equity shares in an open market transaction on November 6, 2026, reducing its shareholding from 74.73% to 71.74%. This marks a decrease of 2.99% in voting rights in Alivus Life Sciences Limited, reflecting a notable promoter stake adjustment disclosed under SEBI regulations.
Nirma Limited
Acquisition / Amalgamation / Merger / Demerger
Nirma Limited, a promoter of Alivus Life Sciences Limited, has sold 36,80,000 equity shares in an open market sale on 6th November 2026, decreasing its shareholding to 71.74% from 74.73%.
Before the sale, Nirma Limited held 9,18,96,285 shares constituting 74.73% of the total share capital of Alivus Life Sciences Limited.
The transaction involved an open market sale of shares carrying voting rights, totaling 36,80,000 shares which represent 2.99% of the total shareholding and voting rights.
After the sale, the total shareholding of Nirma Limited in Alivus Life Sciences Limited stands at 8,82,16,285 shares, representing 71.74% of total shares and voting rights.
The total equity share capital of Alivus Life Sciences Limited before and after this transaction is Rs. 24,59,34,562 consisting of 12,29,67,281 equity shares of Rs. 2 each.
The total diluted share/voting capital of Alivus Life Sciences Limited after the transaction is Rs. 24,65,63,958 (12,32,81,979 Equity Shares of Rs. 2 each).
Highlights
- Sale of 36,80,000 equity shares by Nirma Limited on 6th November 2026.
- Promoter shareholding declined by 2.99%, from 74.73% to 71.74%.
- Transaction mode: Open Market sale.
- Equity share capital of Alivus remains Rs. 24,59,34,562 with 12,29,67,281 equity shares of Rs. 2 each.
- Disclosure made under Regulation 29(2) of SEBI SAST Regulations 2011.
Key Data Snapshot
What happened
- Nirma Limited sold 36,80,000 equity shares in Alivus Life Sciences Limited.
- This sale resulted in shareholding decline from 74.73% to 71.74%.
- The shares were sold via open market transaction on 6th November 2026.
- The sale was disclosed as per Regulation 29(2) of SEBI SAST Regulations.
Key details
- Equity share capital of Alivus Life Sciences remains Rs. 24,59,34,562, composed of 12,29,67,281 shares each of Rs. 2.
- Diluted share/voting capital after the transaction is Rs. 24,65,63,958 comprising 12,32,81,979 shares.
- No shares were encumbered or pledged as part of this transaction.
- There were no warrants, convertible securities, or other voting rights instruments involved.
Regulatory and governance context
- Disclosure made under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically Regulation 29(2).
- The promoter group status of Nirma Limited was maintained after the shareholding reduction.
- Details reflect the shareholding based on the latest filings and updated share capital figures provided by Alivus Life Sciences Limited.
Highlights
- Sale of 36,80,000 equity shares by Nirma Limited on 6th November 2026.
- Promoter shareholding declined by 2.99%, from 74.73% to 71.74%.
- Transaction mode: Open Market sale.
- Equity share capital of Alivus remains Rs. 24,59,34,562 with 12,29,67,281 equity shares of Rs. 2 each.
- Disclosure made under Regulation 29(2) of SEBI SAST Regulations 2011.
Disclosures
- SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 29(2)
Yes, Nirma Limited is a promoter of Alivus Life Sciences Limited and the seller of shares.
More News on Acquisition / Amalgamation / Merger / Demerger
View allLatest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.
Tata Motors Subsidiary Acquires 96.25% of Iveco Group Through Tender Offer Finalization
Tata Motors Limited's wholly owned subsidiary, TML CV Holdings B.V., has successfully increased its stake in Iveco Group N.V. to approximately 96.25% of the common share capital following a voluntary totalitarian tender offer and reopening of terms.
Read Full Story
Aequs Limited Obtains Bengaluru Regional Directorate Approval for Subsidiaries’ Amalgamation Scheme Effective April 2026
Aequs Limited has received official sanction from the Bengaluru Regional Directorate for the Scheme of Amalgamation of its three wholly owned subsidiaries, with effect from April 1, 2026, after a successful appeal with the Ministry of Corporate Affairs correcting a prior rejection.
Read Full Story
Alkem Laboratories Incorporates 51% Owned Joint Venture 'Alkem Pharma Company' in Saudi Arabia
Alkem Laboratories Limited has formed a new subsidiary in Saudi Arabia called 'Alkem Pharma Company', a joint venture with Alkem holding 51% of shares through a cash investment of 3,825,000 SAR. The company aims to expand its pharmaceutical and nutraceutical business presence in the Kingdom of Saudi Arabia.
Read Full Story
